IGF1 and myocardial infarction: These findings align with previous research supporting IGF1 as a cardioprotective factor [21,22,61,62], and provide evidence for tissue-engineered cardiac patches as an in vivo delivery platform for therapeutic cells enriched with key modified mRNAs to the infarct heart for the repair of MI.